<doc>
  <docmeta id="113hr3005ih">
    <bill congress="113" type="hr" number="3005" version="ih"/>
    <revision size="2836" annotations="0" status="complete" id="3" commit-time="2013-08-18T16:32:10Z" committer="mbohmer" doc="113hr3005ih/3.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HB9747C5510D94C45A970924E4FE0D6F2" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>113 HR 3005 IH: Medical Testing Availability Act of 2013</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2013-08-02</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 3005</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20130802">August 2, 2013</action-date>
			<action-desc>
        <sponsor name-id="B001248">Mr. Burgess</sponsor> (for
			 himself and <cosponsor name-id="S001175">Ms. Speier</cosponsor>) introduced the
			 following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and
			 Commerce</committee-name>
      </action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend chapter V of the Federal Food, Drug, and
		  Cosmetic Act to permit the sale of, and access to, <quote>research use
		  only</quote> products in diagnostic tests.</official-title>
	</form>
	<legis-body id="HDDC0FDDBD17F42E1843ED9FF72944B3A" style="OLC">
		<section id="HC8502C575282435C88FE5D44E081CAB5" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the
			 <quote>
          <short-title>Medical Testing Availability Act of
			 2013</short-title>
        </quote>.</text>
		</section>
    <section id="H5CEDF01B45AC4F1A967259935DCA9F27">
      <enum>2.</enum>
      <header>Clarification
			 regarding research use only products</header>
      <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:520">Section 520 of the Federal Food, Drug, and
			 Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/360j">
            <cato:entity-ref entity-type="uscode" value="usc/21/360j">21 U.S.C. 360j</cato:entity-ref>
          </external-xref>)</cato:entity> is amended by adding at the end the following
			 subsection:</text>
			<quoted-block id="HB86032CC870D4518BD2CA99B9F73B431" style="OLC">
				<subsection id="H7BE287051A284B87B9ECF4F0EA56BD5E">
          <enum>(o)</enum>
          <header>Products with
				research use only labeling</header>
					<paragraph id="H14AA9990CB1B4D3E8E73D582E3D57699">
            <enum>(1)</enum>
            <header>In
				general</header>
            <text display-inline="yes-display-inline">A product whose
				labeling bears the statement described in <external-xref legal-doc="usc" parsable-cite="usc/21/809">section 809.10(c)(2)(i)</external-xref> of title 21,
				Code of Federal Regulations, as in effect on the date of the enactment of this
				subsection, may not be deemed to be misbranded under this Act on the basis that
				the manufacturer or distributor of the product—</text>
						<subparagraph commented="no" id="H64443D4A383F43E2B4213EF9720D65E2">
              <enum>(A)</enum>
              <text display-inline="yes-display-inline">sells the product to an end user who uses
				the product in a manner inconsistent with such statement; or</text>
						</subparagraph>
            <subparagraph id="HFC968723BFA347EA853EEDFD543BE112">
              <enum>(B)</enum>
              <text>engages in
				business communications regarding the product with an end user of the
				product.</text>
						</subparagraph>
          </paragraph>
          <paragraph id="HB406981C74E14A04936F99134EB4F843">
            <enum>(2)</enum>
            <header>Business
				communications defined</header>
            <text display-inline="yes-display-inline">In
				this subsection, the term <term>business communications</term>, with respect to
				a product with labeling described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:520/ss:o/p:1" proposed="true">paragraph (1)</cato:entity-ref>—</text>
						<subparagraph id="H8E2DEA37FCA643C085B5462E87684453">
              <enum>(A)</enum>
              <text>means oral,
				written, or electronic contact between a manufacturer or distributor of such
				product and an end user regarding the functioning of such product; and</text>
						</subparagraph>
            <subparagraph id="H163E27908E8646B78B41A2A47763D6E5">
              <enum>(B)</enum>
              <text>includes any such
				contact consisting of technical support, customer service, assistance with the
				installation of such product, communication relating to ensuring the
				performance of the product, and other similar contacts.</text>
						</subparagraph>
          </paragraph>
          <paragraph id="HFB4756C3FF3D4CFC9EACEF0B3C721927">
            <enum>(3)</enum>
            <header>Sunset</header>
            <text>This
				subsection shall cease to be effective on the last day of the five-year period
				beginning on the date of enactment of this section.</text>
					</paragraph>
        </subsection>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
		</section>
  </legis-body>
</bill>
</doc>